Name | Number of supported studies | Average coverage | |
---|---|---|---|
GABAergic neuron | 5 studies | 29% ± 11% | |
astrocyte | 4 studies | 25% ± 11% | |
glutamatergic neuron | 4 studies | 43% ± 17% | |
hematopoietic precursor cell | 3 studies | 20% ± 2% | |
transit amplifying cell | 3 studies | 40% ± 25% | |
interneuron | 3 studies | 36% ± 13% | |
erythroblast | 3 studies | 25% ± 10% | |
natural killer cell | 3 studies | 19% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 274.11 | 1438 / 1445 | 100% | 10.61 | 183 / 183 |
uterus | 100% | 323.10 | 170 / 170 | 98% | 7.12 | 451 / 459 |
lung | 99% | 303.76 | 575 / 578 | 98% | 5.50 | 1134 / 1155 |
bladder | 100% | 223.38 | 21 / 21 | 97% | 5.32 | 490 / 504 |
breast | 100% | 308.55 | 459 / 459 | 97% | 4.63 | 1084 / 1118 |
intestine | 100% | 310.60 | 965 / 966 | 96% | 4.82 | 508 / 527 |
stomach | 99% | 207.10 | 356 / 359 | 96% | 5.77 | 275 / 286 |
ovary | 100% | 341.44 | 180 / 180 | 95% | 2.95 | 407 / 430 |
pancreas | 94% | 121.11 | 308 / 328 | 93% | 2.51 | 165 / 178 |
skin | 100% | 510.71 | 1805 / 1809 | 86% | 3.56 | 404 / 472 |
brain | 91% | 216.27 | 2401 / 2642 | 92% | 2.88 | 651 / 705 |
thymus | 100% | 246.83 | 652 / 653 | 74% | 1.90 | 447 / 605 |
kidney | 99% | 144.80 | 88 / 89 | 69% | 1.58 | 620 / 901 |
prostate | 100% | 261.13 | 245 / 245 | 61% | 1.04 | 308 / 502 |
liver | 86% | 102.32 | 195 / 226 | 52% | 1.30 | 213 / 406 |
adrenal gland | 98% | 150.14 | 252 / 258 | 39% | 0.67 | 90 / 230 |
adipose | 100% | 243.38 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 6.35 | 29 / 29 |
spleen | 100% | 510.79 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 8.04 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.74 | 1 / 1 |
blood vessel | 95% | 145.28 | 1270 / 1335 | 0% | 0 | 0 / 0 |
heart | 80% | 90.09 | 691 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 61% | 721.44 | 565 / 929 | 0% | 0 | 0 / 0 |
muscle | 56% | 52.39 | 446 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 31% | 0.48 | 25 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1902751 | Biological process | positive regulation of cell cycle G2/M phase transition |
GO_0090618 | Biological process | DNA clamp unloading |
GO_0008283 | Biological process | cell population proliferation |
GO_0033260 | Biological process | nuclear DNA replication |
GO_0042771 | Biological process | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
GO_0045740 | Biological process | positive regulation of DNA replication |
GO_0048304 | Biological process | positive regulation of isotype switching to IgG isotypes |
GO_0030890 | Biological process | positive regulation of B cell proliferation |
GO_1902166 | Biological process | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
GO_0045190 | Biological process | isotype switching |
GO_1901990 | Biological process | regulation of mitotic cell cycle phase transition |
GO_0042770 | Biological process | signal transduction in response to DNA damage |
GO_0031391 | Cellular component | Elg1 RFC-like complex |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0061860 | Molecular function | DNA clamp unloader activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
GO_0016887 | Molecular function | ATP hydrolysis activity |
Gene name | ATAD5 |
Protein name | ATPase family AAA domain-containing protein 5 (Chromosome fragility-associated gene 1 protein) ATPase family AAA domain containing 5 |
Synonyms | C17orf41 Elg1 FRAG1 |
Description | FUNCTION: Has an important role in DNA replication and in maintaining genome integrity during replication stress . Involved in a RAD9A-related damage checkpoint, a pathway that is important in determining whether DNA damage is compatible with cell survival or whether it requires cell elimination by apoptosis . Modulates the RAD9A interaction with BCL2 and thereby induces DNA damage-induced apoptosis . Promotes PCNA deubiquitination by recruiting the ubiquitin-specific protease 1 (USP1) and WDR48 thereby down-regulating the error-prone damage bypass pathway . As component of the ATAD5 RFC-like complex, regulates the function of the DNA polymerase processivity factor PCNA by unloading the ring-shaped PCNA homotrimer from DNA after replication during the S phase of the cell cycle . This seems to be dependent on its ATPase activity . Plays important roles in restarting stalled replication forks under replication stress, by unloading the PCNA homotrimer from DNA and recruiting RAD51 possibly through an ATR-dependent manner . Ultimately this enables replication fork regression, breakage, and eventual fork restart . Both the PCNA unloading activity and the interaction with WDR48 are required to efficiently recruit RAD51 to stalled replication forks . Promotes the generation of MUS81-mediated single-stranded DNA-associated breaks in response to replication stress, which is an alternative pathway to restart stalled/regressed replication forks . . |
Accessions | ENST00000321990.5 [Q96QE3-1] A0A075B754 Q96QE3 ENST00000578295.5 |